DK3977993T3 - Krystallinske faste former af 6-carboxy-2-(3,5-dichlorphenyl)-benzoxazol til anvendelse som et medikament - Google Patents

Krystallinske faste former af 6-carboxy-2-(3,5-dichlorphenyl)-benzoxazol til anvendelse som et medikament Download PDF

Info

Publication number
DK3977993T3
DK3977993T3 DK21203965.5T DK21203965T DK3977993T3 DK 3977993 T3 DK3977993 T3 DK 3977993T3 DK 21203965 T DK21203965 T DK 21203965T DK 3977993 T3 DK3977993 T3 DK 3977993T3
Authority
DK
Denmark
Prior art keywords
benzoxazole
dichlorophenyl
carboxy
medicament
crystalline solid
Prior art date
Application number
DK21203965.5T
Other languages
English (en)
Inventor
Kevin Paul Girard
Andrew J Jensen
Kris Nicole Jones
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54199901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3977993(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK3977993T3 publication Critical patent/DK3977993T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
DK21203965.5T 2014-09-08 2015-08-31 Krystallinske faste former af 6-carboxy-2-(3,5-dichlorphenyl)-benzoxazol til anvendelse som et medikament DK3977993T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462047614P 2014-09-08 2014-09-08
US201562203953P 2015-08-12 2015-08-12
EP15771276.1A EP3191461B1 (en) 2014-09-08 2015-08-31 Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole

Publications (1)

Publication Number Publication Date
DK3977993T3 true DK3977993T3 (da) 2024-02-19

Family

ID=54199901

Family Applications (2)

Application Number Title Priority Date Filing Date
DK21203965.5T DK3977993T3 (da) 2014-09-08 2015-08-31 Krystallinske faste former af 6-carboxy-2-(3,5-dichlorphenyl)-benzoxazol til anvendelse som et medikament
DK24152053.5T DK4349406T3 (da) 2014-09-08 2015-08-31 Kristalliske faststofformer af 6-carboxy-2-(3,5-dichlorphenyl)-benzoxazol til brug som lægemiddel

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK24152053.5T DK4349406T3 (da) 2014-09-08 2015-08-31 Kristalliske faststofformer af 6-carboxy-2-(3,5-dichlorphenyl)-benzoxazol til brug som lægemiddel

Country Status (24)

Country Link
US (1) US9770441B1 (da)
EP (3) EP3977993B1 (da)
JP (5) JP2016065042A (da)
KR (1) KR102004059B1 (da)
CN (2) CN115368313A (da)
AU (1) AU2015313875B2 (da)
BR (1) BR112017003421B1 (da)
CA (1) CA2903194A1 (da)
CY (1) CY1124843T1 (da)
DK (2) DK3977993T3 (da)
ES (3) ES3061774T3 (da)
FI (2) FI3977993T3 (da)
HR (1) HRP20211834T1 (da)
HU (2) HUE056583T2 (da)
IL (1) IL251037B1 (da)
LT (1) LT3191461T (da)
MX (1) MX374012B (da)
PL (3) PL3191461T3 (da)
PT (3) PT4349406T (da)
RS (1) RS62634B1 (da)
SG (1) SG11201700958YA (da)
SI (3) SI4349406T1 (da)
TW (1) TWI644902B (da)
WO (1) WO2016038500A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2571950A (en) * 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
WO2020128816A2 (en) 2018-12-20 2020-06-25 Pfizer Inc. Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
US12116352B2 (en) 2019-04-11 2024-10-15 Inke, S.A. Process for preparing 1-deoxy-1-methylamino-d-glucitol 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate
US12391656B2 (en) 2019-05-16 2025-08-19 Assia Chemical Industries Ltd. Solid state forms of Tafamidis and salts thereof
US20220251052A1 (en) * 2019-07-04 2022-08-11 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof
JP2023503833A (ja) 2019-11-15 2023-02-01 ▲蘇▼州科睿思制▲葯▼有限公司 タファミジスの結晶形及びその調製方法及びその使用
EP4077287B1 (en) 2019-12-20 2025-11-19 Pfizer Ireland Pharmaceuticals Unlimited Company Efficient process for making 6-carboxy benzoxazole derivatives
WO2021152623A1 (en) * 2020-01-27 2021-08-05 Dr. Reddy’S Laboratories Limited Improved processes for the preparation of tafamidis and its meglumine salt
WO2021232619A1 (zh) * 2020-05-19 2021-11-25 苏州科睿思制药有限公司 一种他发米帝司游离酸的晶型及其制备方法和用途
US20230265059A1 (en) * 2020-07-04 2023-08-24 Nuray Chemicals Private Limited Solid state forms of 6-carboxy-2-(3, 5-dichlorophenyl)-benzoxazole of formula-i and pharmaceutically acceptable salts thereof
EP4228629A4 (en) * 2020-10-19 2024-12-25 Glenmark Life Sciences Limited PROCESS FOR PREPARING TAFAMIDIS AND SALTS THEREOF
WO2022107166A1 (en) * 2020-11-20 2022-05-27 Natco Pharma Limited Novel crystalline form of tafamidis and its process thereof
WO2022112919A1 (en) 2020-11-25 2022-06-02 Pfizer Inc. (aza)benzothiazolyl substituted pyrazole compounds
CN114907283B (zh) * 2021-02-07 2025-01-28 南京正大天晴制药有限公司 一种2-(3，5-二氯苯基)-苯并噁唑-6-羧酸的制备方法
CN114989106A (zh) * 2021-02-09 2022-09-02 齐鲁制药有限公司 氯苯唑酸的新晶型及其制备方法
EP4083027A1 (en) 2021-04-26 2022-11-02 Química Sintética, S.A. A solid state form of tafamidis and a process for its preparation
WO2023020762A1 (en) 2021-08-16 2023-02-23 Synthon B.V. Crystalline forms of tafamidis nicotinamide adduct
WO2023091534A1 (en) 2021-11-17 2023-05-25 Teva Pharmaceuticals International Gmbh Solid state form of tafamidis
CN119604278A (zh) 2022-07-28 2025-03-11 辉瑞大药厂 氯苯唑酸药物组合物
WO2024084362A1 (en) * 2022-10-17 2024-04-25 Biophore India Pharmaceuticals Pvt. Ltd A process for the preparation of crystalline form of tafamidis
US11878081B1 (en) 2022-12-23 2024-01-23 Tap Pharmaceuticals Ag Pharmaceutical formulations of tafamidis
US11980685B1 (en) 2022-12-23 2024-05-14 Tap Pharmaceuticals, Ag Liquid pharmaceutical formulations of tafamidis
WO2026050334A1 (en) 2024-08-29 2026-03-05 Alexion Pharmaceuticals, Inc. Transthyretin stabilizers and methods of use thereof
EP4717262A1 (en) 2024-09-26 2026-04-01 Galenicum Health S.L.U. Pharmaceutical compositions of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid
EP4717261A1 (en) 2024-09-26 2026-04-01 Galenicum Health S.L.U. Pharmaceutical compositions of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
ATE405840T1 (de) 2002-12-19 2008-09-15 Scripps Research Inst Zusammensetzungen und verfahren zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung
JP5495787B2 (ja) * 2006-12-06 2014-05-21 クオナトウス ファーマシューティカルズ，インコーポレイテッド （３Ｓ）−３−［Ｎ−（Ｎ’−（２−ｔｅｒｔ−ブチルフェニル）オキサミル）アラニニル］アミノ−５−（２’，３’，５’，６’−テトラフルオロフェノキシ）−４−オキソペンタン酸の結晶形態
US8576985B2 (en) 2009-09-01 2013-11-05 Aptuit (West Lafayette) Llc Methods for indexing solid forms of compounds
RU2586330C2 (ru) 2011-09-16 2016-06-10 Пфайзер Инк. Твердые формы ингибитора диссоциации транстиретина
WO2013168014A1 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
GB2571950A (en) 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
US12391656B2 (en) 2019-05-16 2025-08-19 Assia Chemical Industries Ltd. Solid state forms of Tafamidis and salts thereof
US20220251052A1 (en) 2019-07-04 2022-08-11 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof
WO2021152623A1 (en) 2020-01-27 2021-08-05 Dr. Reddy’S Laboratories Limited Improved processes for the preparation of tafamidis and its meglumine salt

Also Published As

Publication number Publication date
TWI644902B (zh) 2018-12-21
JP2020055832A (ja) 2020-04-09
SG11201700958YA (en) 2017-03-30
RU2017107235A (ru) 2018-10-11
JP2025108584A (ja) 2025-07-23
JP7357525B2 (ja) 2023-10-06
PT4349406T (pt) 2026-02-04
IL251037B1 (en) 2024-10-01
PT3191461T (pt) 2021-12-27
RU2692252C2 (ru) 2019-06-24
JP2022024014A (ja) 2022-02-08
RS62634B1 (sr) 2021-12-31
FI4349406T3 (fi) 2026-02-04
HUE056583T2 (hu) 2022-02-28
EP3977993A1 (en) 2022-04-06
JP2016065042A (ja) 2016-04-28
EP3191461A1 (en) 2017-07-19
LT3191461T (lt) 2021-12-10
HRP20211834T1 (hr) 2022-03-04
DK4349406T3 (da) 2026-02-02
FI3977993T3 (fi) 2024-03-25
ES2975633T3 (es) 2024-07-10
SI3191461T1 (sl) 2022-01-31
AU2015313875B2 (en) 2018-03-15
US9770441B1 (en) 2017-09-26
HUE065233T2 (hu) 2024-05-28
US20170273953A1 (en) 2017-09-28
WO2016038500A1 (en) 2016-03-17
NZ729011A (en) 2023-10-27
SI3977993T1 (sl) 2024-05-31
AU2015313875A1 (en) 2017-03-02
CN106715405A (zh) 2017-05-24
MX2017002954A (es) 2017-06-15
EP3191461B1 (en) 2021-11-03
TW201613880A (en) 2016-04-16
SI4349406T1 (sl) 2026-02-27
PL4349406T3 (pl) 2026-03-23
ES3061774T3 (en) 2026-04-07
NZ766084A (en) 2023-12-22
CY1124843T1 (el) 2022-11-25
CA2903194A1 (en) 2016-03-08
PT3977993T (pt) 2024-04-01
IL251037A0 (en) 2017-04-30
MX374012B (es) 2020-07-22
EP4349406A3 (en) 2024-05-22
KR20170040314A (ko) 2017-04-12
EP4349406B1 (en) 2025-12-03
EP4349406A2 (en) 2024-04-10
BR112017003421A2 (pt) 2017-11-28
PL3977993T3 (pl) 2024-05-06
EP3977993B1 (en) 2024-01-31
ES2901785T3 (es) 2022-03-23
RU2017107235A3 (da) 2018-10-11
JP2023134645A (ja) 2023-09-27
CN115368313A (zh) 2022-11-22
BR112017003421B1 (pt) 2023-10-10
PL3191461T3 (pl) 2022-02-07
KR102004059B1 (ko) 2019-07-25

Similar Documents

Publication Publication Date Title
DK4349406T3 (da) Kristalliske faststofformer af 6-carboxy-2-(3,5-dichlorphenyl)-benzoxazol til brug som lægemiddel
IL283258A (en) Treatment of hypoparathyroidism
DK3372584T3 (da) Fremgangsmåde til fremstillingen af en diarylthiohydantoin-forbindelse
DK3099333T3 (da) Bag3 som mål for behandling af hjertesvigt
DK3094631T3 (da) Pyrimidinyloxybenzenderivater som herbicider
DK3130592T3 (da) ANALOGER AF 4H-PYRAZOLO[1,5-á]BENZIMIDAZOL-FORBINDELSER SOM PARPINHIBITORER
DK3357919T3 (da) Aromatiske heterocykliske forbindelser som antiinflammatoriske forbindelser
DK3998070T3 (da) Mir-124 som biomarkør til behandling af inflammatoriske sygdomme
DK3237410T3 (da) Azolinforbindelser, der er substitueret med et kondenseret ringsystem
DK3325487T3 (da) Formulering til bløde, anticholinerge analoger
DK3233843T3 (da) Isoxazol-hydraxamsyreforbindelser som LPXC-hæmmere
DK3189043T3 (da) Terapeutiske forbindelser som hæmmere af orexin-1-receptoren
DK3233813T3 (da) Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser
DK3103453T3 (da) Medicinsk sammensætning omfattende heterocyklisk diamino-carboxamidforbindelse som aktiv bestanddel
IL250038A0 (en) 4,5 - dehydroisoxazole derivatives used as nampt inhibitors
HUE042349T2 (hu) Eljárás diariltiohidantoin vegyület elõállítására
LT3597189T (lt) Kristaliniai junginia
IL250211A0 (en) A process for the preparation of optically active isoxazoline compounds
BR112017013013A2 (pt) combinações de composto ativo
DK3186227T3 (da) Nye sulfonylaminobenzamid-forbindelser som anthelmintika
DK3138840T3 (da) Thiadiazolidin-derivat som anti-enterovirus 71
DK3298042T3 (da) B-celledepletering som en diagnostisk markør
BR112016018011A2 (pt) kit para a preparação de um produto radiofarmacêutico
TH1501006442A (th) รูปดัดแปรผลึกของอีโลไบซิแบต
ITUA20164587A1 (it) Dispositivo di fissaggio di un arresto.